Pemvidutide Drug Asset Due Diligence Report 2026

This Pemvidutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pemvidutide can convert its Synthetic peptide profile and GCGR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pemvidutide (query alias: pemvidutide)
Modality / target	Synthetic peptide; GCGR x GLP-1R; GCGR agonists, GLP-1R agonists
Highest global status	Phase 3
Originator	Altimmune, Inc.
Active developers	Altimmune, Inc.

The MCP disease footprint includes Metabolic Dysfunction Associated Steatohepatitis, Obesity, Liver Diseases, Alcoholic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05295875	Phase 2	Completed	391	Relative change from baseline in body weight percentage
NCT05989711	Phase 2	Completed	212	Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis
NCT07009860	Phase 2	Recruiting	100	Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Phase 2; n=212; evaluation: Positive. Reported fields: ELF(at week 48,mean reduction from baseline) = -0.58 Point ; ELF(at week 48,mean reduction from baseline) = -0.49 Point ; ELF(at week 48,mean reduction from baseline) = +0.16 Point

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Phase 2; n=212; evaluation: Positive. Reported fields: MASH resolution without fibrosis worsening(at 24 weeks) = 45 Pts Met; MASH resolution without fibrosis worsening(at 24 weeks) = 24 Pts Met; MASH resolution without fibrosis worsening(at 24 weeks) = 18 Pts Met

Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial

Phase 3; n=64; evaluation: Positive. Reported fields: Body weight: P-Value = <0.001; P-Value = <0.001; P-Value = <0.001; Body weight: P-Value = <0.001; P-Value = <0.001; P-Value = <0.001; Body weight: P-Value = <0.001; P-Value = <0.001; P-Value = <0.001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pemvidutide addresses Metabolic Dysfunction Associated Steatohepatitis, Obesity, Liver Diseases, Alcoholic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-07-08	Spitfire and Mederis Diabetes enter into an amended and restated license agreement	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Therapeutic regimens and methods for reducing body weight and/or serum lipids using a GLP-1r and GCGR agonist”. The milestone feed surfaced a patent-application signal described as “Composition comprising a GLP1r agonist and engineered extracellular vesicles comprising adiponectin, and uses thereof”. The milestone feed surfaced a patent-application signal described as “Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO